The present invention relates to a medical device to be applied to a body of a human or animal being. The medical device comprises a contact surface to contact the body of the human or animal being when the medical device is applied to the body of the human or animal being. The contact surface is covered with a soluble surface sealing. The surface sealing is composed of an organic compound.

A composition for providing a barrier between tissues and/or organs during or after a surgical procedure. The composition is a flowable solution of a hydrophobically-modified chitosan, wherein the hydrophobic modifications are selected to allow for adherence to tissue, cohesiveness of the composition upon application to tissue, and degradation over about two weeks after application. A method for providing a barrier between tissues and/or organs during or after a surgical procedure. Applying a hydrophobically-modified polymer to surfaces of tissues or organs in within a surgical site either before, during, and/or after a surgical procedure, wherein the modified polymer reduces adhesion between organs or tissues after surgery.

A composition for providing a barrier between tissues and/or organs during or after a surgical procedure. The composition is a flowable solution of a hydrophobically-modified chitosan, wherein the hydrophobic modifications are selected to allow for adherence to tissue, cohesiveness of the composition upon application to tissue, and degradation over about two weeks after application. A method for providing a barrier between tissues and/or organs during or after a surgical procedure. Applying a hydrophobically-modified polymer to surfaces of tissues or organs in within a surgical site either before, during, and/or after a surgical procedure, wherein the modified polymer reduces adhesion between organs or tissues after surgery.

Provided herein are methods for decreasing the toxicity of advanced ablative cancer therapies on neighboring organs. The methods herein provide spacing between single or multiple tumor cites and immediate healthy organs while maintaining or increasing patient quality of life. Such toxicity isolation can be performed by inserting a spacer around the one or more tumor cites, which can be performed concurrently with fiducial marker placement.

Provided herein are methods for decreasing the toxicity of advanced ablative cancer therapies on neighboring organs. The methods herein provide spacing between single or multiple tumor cites and immediate healthy organs while maintaining or increasing patient quality of life. Such toxicity isolation can be performed by inserting a spacer around the one or more tumor cites, which can be performed concurrently with fiducial marker placement.

An object is to provide a subcutaneous or submucosal expansion agent that not only has superior expansion properties to those of conventional agents, and maintains the expanded state for a relatively long period of time, but also ensures sufficient administration properties. The subcutaneous or submucosal expansion agent is injected into a subcutaneous or submucosal space to expand the subcutaneous or submucosal space, and comprises cellulose fibers (A) containing anionically modified cellulose, and water (B).

An object is to provide a subcutaneous or submucosal expansion agent that not only has superior expansion properties to those of conventional agents, and maintains the expanded state for a relatively long period of time, but also ensures sufficient administration properties. The subcutaneous or submucosal expansion agent is injected into a subcutaneous or submucosal space to expand the subcutaneous or submucosal space, and comprises cellulose fibers (A) containing anionically modified cellulose, and water (B).

A heterogeneous patient-based breast phantom that mimics the anatomy and properties of real breast tissues when screened with ionizing and nonionizing imaging modalities is described. The heterogeneous breast phantom includes a skin mimicking segment; an adipose tissue mimicking segment; a fibro-glandular tissue mimicking segment; and a pectoral muscle mimicking segment wherein each segment is shaped and arranged such that the breast phantom represents a breast tissue. Performance of the breast phantom was characterized by mass attenuation coefficient, electron density and effective atomic number. Further, performance of breast phantoms was confirmed CT and breast MM machines.

A transponder includes an encapsulant defining a cavity having a spherical internal profile. A suspension medium and a core are contained within the cavity. The core includes a rod having a first end and a second end, and defines a longitudinal axis between the first end and the second end. The longitudinal axis of the rod defines an axis of sensitivity of the transponder, and the core defines a center of gravity closer to the second end of the rod as compared to the first end of the rod. The center of gravity is disposed along the longitudinal axis of the rod. The transducer includes a conductive coil wrapped around the rod, and a capacitor coupled to the conductive coil. The core self-orients itself such that the axis of sensitivity of the transponder is parallel with a plumb to gravity axis.

Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G′) of at least about 500 Pa.